JP2024543385A - Ｓｉｒｐガンマ抗体及びその使用 - Google Patents

Ｓｉｒｐガンマ抗体及びその使用 Download PDF

Info

Publication number
JP2024543385A
JP2024543385A JP2024527394A JP2024527394A JP2024543385A JP 2024543385 A JP2024543385 A JP 2024543385A JP 2024527394 A JP2024527394 A JP 2024527394A JP 2024527394 A JP2024527394 A JP 2024527394A JP 2024543385 A JP2024543385 A JP 2024543385A
Authority
JP
Japan
Prior art keywords
seq
amino acid
cells
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543385A5 (https=
Inventor
パニッカー，サンディップ
デイビッド ローゼンタール，アダム
リンシュー ローズ，アイリーン
グオ ヤン ツァイ，アレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Electra Therapeutics Inc
Original Assignee
Electra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electra Therapeutics Inc filed Critical Electra Therapeutics Inc
Publication of JP2024543385A publication Critical patent/JP2024543385A/ja
Publication of JP2024543385A5 publication Critical patent/JP2024543385A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024527394A 2021-11-10 2022-11-10 Ｓｉｒｐガンマ抗体及びその使用 Pending JP2024543385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163277966P 2021-11-10 2021-11-10
US63/277,966 2021-11-10
PCT/US2022/079668 WO2023086906A2 (en) 2021-11-10 2022-11-10 Sirp gamma antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024543385A true JP2024543385A (ja) 2024-11-21
JP2024543385A5 JP2024543385A5 (https=) 2025-11-19

Family

ID=84488592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527394A Pending JP2024543385A (ja) 2021-11-10 2022-11-10 Ｓｉｒｐガンマ抗体及びその使用

Country Status (11)

Country Link
US (1) US20240400677A1 (https=)
EP (1) EP4429768A2 (https=)
JP (1) JP2024543385A (https=)
KR (1) KR20240099454A (https=)
CN (1) CN118591556A (https=)
AU (1) AU2022386652A1 (https=)
CA (1) CA3237787A1 (https=)
IL (1) IL312776A (https=)
MX (1) MX2024005740A (https=)
TW (1) TW202334224A (https=)
WO (1) WO2023086906A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用
WO2025226685A1 (en) * 2024-04-22 2025-10-30 Electra Therapeutics, Inc. Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
JP7763666B2 (ja) * 2019-06-24 2025-11-04 アムジェン インコーポレイテッド 癌治療のためのＳＩＲＰγの阻害

Also Published As

Publication number Publication date
TW202334224A (zh) 2023-09-01
US20240400677A1 (en) 2024-12-05
KR20240099454A (ko) 2024-06-28
CA3237787A1 (en) 2023-05-19
MX2024005740A (es) 2024-08-06
AU2022386652A1 (en) 2024-06-06
WO2023086906A3 (en) 2023-06-22
WO2023086906A2 (en) 2023-05-19
EP4429768A2 (en) 2024-09-18
IL312776A (en) 2024-07-01
CN118591556A (zh) 2024-09-03

Similar Documents

Publication Publication Date Title
KR102422411B1 (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
EP2994488B1 (en) Use of c5ar antagonists
US20240400677A1 (en) Sirp gamma antibodies and uses thereof
JP7170331B2 (ja) 固形及び血液癌の治療のための併用療法
CN114007699A (zh) 拮抗剂抗cd7抗体
RS65804B1 (sr) Humanizovana anti-il-1r3 antitela
KR20220129030A (ko) 항-Gal3 항체 및 사용 방법
KR20230017793A (ko) Sirp 알파 및 sirp 베타 1 항체 및 이의 용도
JP7843824B2 (ja) 抗体および使用方法
KR20240152879A (ko) 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
CA3207703A1 (en) Anti-s100a4 humanized antibodies, uses and methods
KR20190130506A (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도
CN108473586B (zh) 抗cd27抗体、其抗原结合片段及其医药用途
CN111295395A (zh) 抗体和使用方法
KR20210031913A (ko) 항-인간 pd-l1 항체 및 그것의 용도
KR20240055852A (ko) D3-결합 분자 및 이의 용도
AU2022298850B2 (en) Anti-ccr8 antibodies and uses thereof
US20250101008A1 (en) Heterobifunctional molecules for binding ccr2 and methods of treating medical conditions using same
KR20220053000A (ko) Cr2 결합 단백질 및 의료 요법에서의 그의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251110